| Date Filed | Type | Description |
| 09/08/2020 |
GN
| Biopharma Leaders Unite to Stand with Science |
| 08/17/2020 |
GN
| PRINCIPIA BIOPHARMA INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout |
| 03/27/2020 |
GN
| Sanofi Pasteur and Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19 |
| 12/26/2018 |
GN
| Opiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi |
| 09/26/2018 |
GN
| New Research Coverage Highlights Sanofi, Amdocs, GlaxoSmithKline plc, BT Group, Sociedad Quimica y Minera S.A, and ARMOUR Residential REIT — Consolidated Revenues, Company Growth, and Expectations for 2018 |
| 05/22/2018 |
GN
| FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes |
| 03/27/2018 |
GN
| Consolidated Research: 2018 Summary Expectations for Anheuser-Busch InBev SA/NV, Sanofi, Sogou Inc. Sponsored ADR, Unilever, Janus Capital Group, and Kosmos Energy — Fundamental Analysis, Key Performance Indications |
| 09/20/2017 |
BW
| Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy |
| 11/17/2011 |
PRN
| Hagens Berman: Patients Seek to Force FDA to Release Records Showing US Distribution of Thalidomide |
| 07/06/2011 |
BW
| Rib-X Pharmaceuticals and Sanofi Sign a Research Collaboration Agreement on Novel Classes of Antibiotics |
| 05/24/2011 |
BW
| Genzyme Corporation Commences Consent Solicitation Relating to its Outstanding 3.625% Senior Notes due 2015 and 5.000% Senior Notes due 2020 |
| 04/28/2011 |
BW
| Genzyme Revenues Grow in First-Quarter 2011 |
| 04/14/2011 |
BW
| Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease |